S
Surrozen, Inc. (SRZN)
NCM – Real vaqt narxi. Valyuta: USD
30.66
+1.38 (4.71%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
30.66
+1.38 (4.71%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Surrozen, Inc., biotexnologiya kompaniyasi, to'qimalarni tiklash uchun Wnt yo'lini tanlab modulyatsiya qilish uchun mahsulot nomzodlarini kashf etadi va ishlab chiqadi. Uning asosiy mahsulot nomzodlari ko'z, ichak, jigar, o'pka, retina, buyrak, koklea, kornea, teri, oshqozon osti bezi va markaziy asab tizimi kasalliklari kabi turli kasallik sohalariga qaratilgan antitelaga asoslangan terapevtik vositalardir. Kompaniya SZN-814 ni ishlab chiqadi, u Frizzled 4 (Fzd4 agonizmi) va tomir endotelial o'sish omili (VEGF antagonizmi) ni birlashtirib, diabetik makula shishi (DME), neovaskulyar yoshga bog'liq makula degeneratsiyasi (nam AMD) va retinopatiya ko'rsatkichlarini davolash uchun mo'ljallangan; SZN-8143, u Fzd4 agonizmi, VEGF antagonizmi va interleykin-6 yoki IL-6 ni DME/nam AMD/uveitik makula shishini davolash uchun birlashtiradi; va SZN-413, Fzd4 ga qaratilgan bi-spesifik antiteladir, u retinaning tomir bilan bog'liq kasalliklarini davolash uchun ishlatiladi. Surrozen, Inc. Fzd4 bi-spesifik antitelalarini tadqiq qilish, ishlab chiqish va tijoratlashtirish bo'yicha Boehringer Ingelheim International GmbH bilan hamkorlik va litsenziyalash shartnomasiga; vaTGF-β ni rivojlantiruvchi o'sish omiliga qaratilgan antitelali terapevtik vositalarni kashf qilish bo'yicha TCGFB, Inc. bilan ilmiy hamkorlik shartnomasiga ega, bu idiopatik o'pka fibrozidan aziyat chekayotgan bemorlarni davolash uchun mo'ljallangan. Surrozen, Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor |
| Dr. Daniel L. Chao M.D., Ph.D. | VP & Head of Clinical Development |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Yang Li Ph.D. | Executive Vice President of Research |
| Esther Jhun | Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | srzn-20260331.htm |
| 2026-04-01 | DEF 14A | srzn-20260401.htm |
| 2026-03-23 | S-8 | srzn-20260323.htm |
| 2026-03-23 | S-3 | srzn-20260323.htm |
| 2026-01-30 | 8-K | srzn-20260126.htm |
| 2025-11-07 | 10-Q | srzn-20250930.htm |
| 2025-10-17 | 8-K | srzn-20251014.htm |
| 2025-08-08 | S-8 | srzn-20250808.htm |
| 2025-05-21 | CORRESP | filename1.htm |
| 2025-05-20 | S-3 | srzn_s-3_shelf_202505.htm |
| Mr. Andrew Maleki | Chief Financial Officer |
| Mr. Charles Williams | COO & Corporate Secretary |
| Mr. Craig C. Parker M.B.A. | CEO, President & Director |
| Mr. Michael Lauw M.S.W. | Senior Vice President of Development Operations |